Format

Send to

Choose Destination
J Antibiot (Tokyo). 2016 Feb;69(2):73-88. doi: 10.1038/ja.2015.98. Epub 2015 Oct 14.

A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.

Author information

1
LSE Health, Department of Social Policy, London School of Economics and Political Science, London, UK.
2
Missouri Orthopaedic Institute, University of Missouri, Columbia, MO, USA.

Abstract

Despite the growing threat of antimicrobial resistance, pharmaceutical and biotechnology firms are reluctant to develop novel antibiotics because of a host of market failures. This problem is complicated by public health goals that demand antibiotic conservation and equitable patient access. Thus, an innovative incentive strategy is needed to encourage sustainable investment in antibiotics. This systematic review consolidates, classifies and critically assesses a total of 47 proposed incentives. Given the large number of possible strategies, a decision framework is presented to assist with the selection of incentives. This framework focuses on addressing market failures that result in limited investment, public health priorities regarding antibiotic stewardship and patient access, and implementation constraints and operational realities. The flexible nature of this framework allows policy makers to tailor an antibiotic incentive package that suits a country's health system structure and needs.

PMID:
26464014
PMCID:
PMC4775540
DOI:
10.1038/ja.2015.98
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center